The Angiotensin II receptor blockers market is projected to grow at a CAGR of 3.51%, in terms of value, from USD 7.87 Billion in 2020 to reach USD 10.34 Billion by 2028. This class of drug is used to block angiotensin II effects, and thus prevents the narrowing of blood vessels by angiotensin II action. The Angiotensin II receptor blockers facilitates widening of blood vessels and reduce blood pressure in an individual. In general, Angiotensin II receptor blockers are prescribed for patients with intolerance for angiotensin-converting-enzyme inhibitor.

The key factors contributing to the market growth includes increasing incidence of hypertension, chronic kidney diseases, kidney failure in diabetes, and heat failure, across the globe. For instance, according to American Heart Association statistics 2018, more than 103 million individuals in U.S. suffer from high blood pressure However, associated side effects (such as severe dizziness, insomnia, diarrhea, irregular heartbeat, and confusion) are the major hindrance for market growth during 2019-2026.

Market Overview:

The pharma and healthcare industry is at a crossroads. Patients are benefiting from the promise of cell and gene therapies; uncommon diseases that were previously thought to be incurable are on the verge of finding true treatments. Artificial intelligence (AI) and machine-learning technologies are creating hopes that therapy discovery and development would be more innovative, as well as faster and cheaper. Manufacturing, the supply chain, and the entire healthcare ecosystem all have the potential to benefit from data-driven initiatives. Consumer attitudes and behaviours are shifting in a variety of ways, from growing use of technology and willingness to share data to an interest in using tools to make prescription and treatment decisions. Such factors will drive pharma and healthcare market growth in the coming years.
Some key highlights of the report:

• The reagents consumables segment is expected to account for significant revenue growth over the forecast period. High demand for various reagents for each step during synthesis is boosting segment revenue growth.
• Among the application segments, the therapeutic segment is expected to register highest CAGR between 2021 and 2028. High revenue growth is attributable to growing adoption of oligonucleotides as therapeutic drugs to treat various infectious and rare genetic disorders.
• The hospital segment is expected to account for robust revenue growth throughout the forecast period owing to increasing demand for oligonucleotide drugs to treat various infectious, neurological, and rare genetic diseases along with rise in the number of inpatients and outpatient visits.
• North America accounted for largest market share in terms of revenue in 2020 and is expected to continue dominating other regional markets throughout the forecast period. Factors such as high use of oligonucleotides, well-developed healthcare infrastructure, rapid advancements in genomics, diagnostic screening, and high investments in research and development activities are fueling market revenue growth.
• Asia Pacific is expected to register fastest CAGR of 14.8% over the forecast period owing to increasing government funding for research, growing adoption of therapeutics, and rising awareness about various Angiotensin II receptor blockers applications.
• Agilent Technologies, Inc, ATDBio Ltd., Bio-Synthesis, Inc., BioAutomation Corporation, Thermo Fischer, Scientific, Merck KGaA, LGC Biosearch Technologies, Biogen International, Sarepta Therapeutics, Eurofins Genomics, Eurogentec, GeneDesign, Inc., GE Healthcare, and GenScript, Inc. are leading players operating in the Angiotensin II receptor blockers market.
  Key Players covered in this report are
• In 2019, IDT expanded its courier zones of free next-day delivery service to the scientists in Cambridge, Oxford, and London. This will help IDT grow its customer base.
• In 2019, GenScript introduced to the market the single-stranded DNA service for the CRISPR based gene editing. 
• In 2018, Danaher completed the acquisition of IDT.

Product Outlook (Revenue, USD Billion, 2018 - 2028)

• Reagents Consumables
• Equipment
• Synthesized oligonucleotides
  • DNA oligonucleotides
  • RNA oligonucleotides
• Others

Application Outlook (Revenue, USD Billion, 2018 - 2028)

• Research 
  • Polymerase Chain Reaction (PCR)
  • Sequencing 
  • Others
• Therapeutics
  • Antisense Oligonucleotides 
  • Nucleic Acid Aptamers 
• Diagnostics

End-Use Outlook (Revenue, USD Billion, 2018 - 2028)

• Academic Research Institutes
• Diagnostic Laboratories 
• Pharmaceutical and Biotechnology Companies 
• Hospitals 
• CROs and CMOs

Major Points covered in this report are as below:
 The Angiotensin II receptor blockers Market industry development trends and marketing channels are analyzed. The feasibility of new investment projects are assessed and overall research conclusions offered.
 With the tables and figures, the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.
 Development policies and plans, manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand figures, cost, price, revenue and gross margins.
 The Angiotensin II receptor blockers Market Market report provides key statistics on the market status of the Angiotensin II receptor blockers Market manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.
We can also provide the customized data for separate regions like North America, United States, Canada, Mexico, Asia-Pacific, China, India, Japan, South Korea, Australia, Indonesia, Singapore, Rest of Asia-Pacific, Europe, Germany, France, UK, Italy, Spain, Russia, Rest of Europe, Central South America, Brazil, Argentina, Rest of South America, Middle East Africa, Saudi Arabia, Turkey, Rest of Middle East Africa

Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/946        

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.